Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients: A demonstration project

Journal of Pain and Symptom Management

Volumn 24, Issue 3, 2002, Pages 318-327

  Passik, Steven D ^a,c   Kirsh, Kenneth L ^a   Theobald, Dale ^b   Donaghy, Kathleen ^b   Holtsclaw, Elizabeth ^b   Edgerton, Sarah ^b   Dugan, William ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Gynecologic Cancer Care   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cancer; Depression; Fluoxetine

Indexed keywords

DOXEPIN; FLUOXETINE; METHYLPHENIDATE; MIRTAZAPINE; VENLAFAXINE;

ADULT; AGED; AGITATED DEPRESSION; AGITATION; ALGORITHM; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; MALE; ONCOLOGY; QUALITY OF LIFE; RATING SCALE; SCREENING; SIDE EFFECT; SYMPTOMATOLOGY; TELEPHONE; TREATMENT OUTCOME;

ALGORITHMS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0036758796     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(02)00493-1     Document Type: Article

References (34)

1. Derogatis L., Morrow G., Fetting J. The prevalence of psychiatric disorders among cancer patients. JAMA. 249:1983;751-757.
2. Fulton C. The prevalence and detection of psychiatric morbidity in patients with metastatic breast cancer. Euro J Cancer Care. 7:1998;232-239.
3. Hopwood P., Stephens R.J. Depression in patients with lung cancer. prevalence and risk factors derived from quality of life data J Clin Oncol. 18:2000;893-903.
4. Lynch M.E. The assessment and prevalence of affective disorders in advanced cancer. J Pall Care. 11:1995;10-18.
5. Vernon S.W., Gritz E.R., Peterson S.K.et al. Correlates of psychologic distress in colorectal cancer patients undergoing genetic testing for hereditary colon cancer. Health Psych. 16:1997;73-86.
6. Bottomley A. Depression in cancer patients. a literature review Eur J Cancer Care. 7:1998;181-191.
7. Passik S., Dugan W., McDonald M.et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol. 16:1998;1594-1600.
8. McDonald M., Passik S., Dugan W.et al. Nurses' recognition of depression in their patients with cancer. Oncol Nurs Forum. 3(26):1999;185-193.
9. Passik SD, Theobald DE, Holtsclaw E, et al. The oncology symptom control research (OSCR) program; a psycho-oncology and symptom management program for community-based ambulatory oncology. Symptom Management for the Cancer Patient II 2000.
10. Zung W. Depression in the normal aged. Psychosomatics. 7:1967;287-292.
11. Dugan W., McDonald M., Passik S.et al. Use of the zung self-rating depression scale in cancer patients. feasibility as a screening tool Psycho-Oncol. 7:1998;483-493.
12. Passik S.D., Lundberg J., Rosenfeld B.et al. Factor analysis of the zung self-rating depression scale in a large ambulatory oncology sample. Psychosomatics. 41:2000;121-127.
13. Passik S.D., Donaghy K.B., Theobald D.et al. Oncology staff recognition of depressive symptoms on videotaped interviews of depressed cancer patients. implications for designing a training program J Pain Symptom Manage. 19:2000;329-338.
14. Passik S.D., Kirsh K.L., Donaghy K.B.et al. An attempt to employ the zung self-rating depression scale as a lab test to trigger follow-up in ambulatory oncology clinics. criterion validation and detection J Pain Symptom Manage. 21:2001;273-281.
15. Kirsh K.L., Passik S.D., Holtsclaw E.et al. I get tired for no reason. a single item screening for cancer-related fatigue J Pain Symptom Manage. 22(5):2001;931-937.
16. Passik SD, Whitcomb LA, Kirsh KL, Theobald DE. An unsuccessful attempt to develop a single item screening for insomnia in cancer patients. J Pain Symptom Manage (in press.).
17. Breitbart W., Passik S.D. Psychiatric contributions to palliative care. Doyle E., Hanks G., MacDonald N. The oxford textbook of palliative medicine. 1993;607-626 Oxford University Press, New York.
18. Fawzy F. Psychosocial interventions for patients with cancer. what works and what doesn't Eur J Cancer. 35:1999;1559-1564.
19. McGrath P. Findings from an educational support course for patients with leukemia. Cancer Pract. 7:1999;198-204.
20. Spiegel D., Sephton S.E., Terr A.et al. Effects of psychosocial treatment in prolonging cancer survival may be mediated by neuroimmune pathways. Ann NY Acad Sci. 840:1998;674-683.
21. Holland J.C., Romano S.J., Heiligstein J.H.et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-Oncol. 7:1998;291-300.
22. Passik S.D., Breitbart W.S. Depression in patients with pancreatic carcinoma. diagnostic and treatment issues Cancer. 78:1996;615-626.
23. th Annual Meeting of ASCO, May 12-15, San Francisco, CA. 383A.
24. Passik S.D., McDonald M., Dugan W.et al. Depression in cancer patients recognition and treatment. Medscape Mental Health. 2:1997;1-15.
25. Theobald D, Passik SD, Donaghy K, et al. An investigation of the analgesic and antiemetic efficacy of mirtazapine (Remeron) in cancer pain patients. Pan American Congress of Psychosocial and Behavioral Oncology, October 20-23, 1999, New York, NY.
26. Theobald DE, Passik SD, Kirsh K, et al. An investigation of the efficacy of mirtazapine in cancer pain patients. 52nd Institute on Psychiatric Services, American Psychiatric Association, October 25-29, 2000.
27. Sheehan D., Lecrubier Y., Sheehan K.et al. Comparison of the mini international neuropsychiatric interview (MINI) with the SCID-P and the CIC. a validity study Psychopharm Bull. 31:1995;616.
28. Zung W. Factors influencing the self-rating depression scale. Arch Gen Psychiatry. 16:1967;543-547.
29. Tate D., Forchheimer M., Maynard F.et al. Comparing two measures of depression in spinal cord injury. Rehabilitation Psychology. 38:1993;53-61.
30. Cella D., Tulsky D., Gray G.et al. The functional assessment of cancer therapy scale. development and validation J Clinical Oncology. 11:1993;570-579.
31. Winstead-Fry P., Schultz A. Psychometric analysis of the functional assessment of cancer therapy-general (FACT-G) scale in a rural sample. Cancer. 79:1997;2446-2452.
32. Brady M., Cella D., Mo F.et al. Reliability and validity of the functional assessment of cancer therapy breast quality of life instrument. J Clin Oncol. 15:1997;974-986.
33. Cella D., Bonomi A., Lloyd S.et al. Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer. 12:1995;199-220.
34. Yellen S., Cella D., Webster K.et al. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT-G) measurement system. J Pain Symptom Manage. 13:1997;63-74.